Full Year 2025 Sandoz Group AG Earnings Call Transcript
Key Points
- Sandoz Group AG (SDZNY) achieved a significant milestone with net sales surpassing $11 billion for the first time, driven by a 13% growth in biosimilars at constant exchange rates.
- The company successfully launched several key medicines, including Pyzchiva, Afqlir, Wyost, Jubbonti, and Tyruko, across various markets, reinforcing its leadership in biosimilars.
- Sandoz Group AG (SDZNY) completed the acquisition of Just-Evotec Biologics Europe, enhancing its technology base and accelerating next-generation biosimilar development and manufacturing.
- The construction of a biosimilar hub in Slovenia is progressing well, which will strengthen Sandoz's manufacturing capabilities and ensure quality and scalability.
- The company reported strong financial performance with a 5% net sales growth at constant currencies, a core EBITDA margin expansion by 160 basis points to 21.7%, and a proposed dividend increase by one third to $0.80 per share.
- Sandoz Group AG (SDZNY) faced adverse impacts on its penicillin B2B business due to significant price dumping by Asian suppliers, affecting sales value in the second half of 2025.
- The introduction of minimum import prices in India for some penicillin APIs may divert low-priced supply towards Europe, impacting the company's generic performance in the first half of 2026.
- The company anticipates continued adverse dynamics in its penicillin B2B business in the first half of 2026, which could affect overall performance.
- Sandoz Group AG (SDZNY) expects to incur costs related to the integration of the Just-Evotec business in France, which could impact financial results.
- The company faces challenges in the US market due to complex IP situations and potential delays in biosimilar entry, impacting long-term biosimilar plans.
Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now hand over to Craig Marks, Head of Investor Relations, for his opening remarks.
Thank you, and welcome to the Sandoz full year results call for 2025. Earlier today, we published the press release and an accompanying presentation on our website, which we'll follow on today's call. You can find these documents at sandoz.com investors. Joining me on today's call are Richard Saynor, Chief Executive Officer; and Remco Steenbergen, Chief Financial Officer.
Please turn to Slide 2. Our results announcement presentation and discussion include forward-looking statements. Please see our disclaimer here.
Please turn to Slide 3. Richard will begin today's presentation with the highlights of 2025, followed by an update on the business. Remco will cover the financial performance as well as the guidance for 2026, following the wrap-up of the presentation, we'll be happy to take your questions. And with that, I will now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
